Pharma

Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

INDIANAPOLIS — November 25, 2025 — Eli Lilly and Company (NYSE: LLY) continued its remarkable run on Tuesday, as the first-ever $1 trillion pharmaceutical company saw its stock climb again on the back of fresh analyst upgrades, intensifying obesity-drug momentum

25 November 2025

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Background: Novo vs. Pfizer in the Weight-Loss Drug Race The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market share

4 November 2025

Business News · Healthcare Industry · Mergers & Acquisitions · NYSE:NVO · NYSE:PFE · Obesity Treatment · Pharmaceuticals

Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Company Profile & Background Scienture Holdings, Inc. is a tiny specialty pharmaceutical company focused on developing and commercializing novel formulations that address unmet needs in healthcare globenewswire.com globenewswire.com. The company’s roots trace back to a 2024 merger with TRxADE Health,

4 November 2025

Company Analysis · Financial News · Investment Insights · Pharma Industry · Stock Market

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Stock Price and Recent Performance RANI has seen explosive moves this month. As of the Oct 31 close, Rani Therapeutics stock was $2.20 (up $0.75, +51.7%) stockanalysis.com. This follows a monumental rally: on Oct 17, RANI nearly tripled from ~$0.47 to

31 October 2025

Biotech · Healthcare Innovation · NASDAQ:RANI · Obesity Treatment · Pharmaceutical Industry · Stock Market News

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo’s counter-offer details Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolio reuters.com. According to MarketScreener (Dow Jones

30 October 2025

Biotechnology · Industry News · Mergers & Acquisitions · NYSE:NVO · NYSE:PFE · Obesity Drugs · Pharmaceuticals

MIRA Pharma Stock Skyrockets 100% Overnight as New Pain Drug Outshines Morphine

Stock Soars on Breakthrough Announcement MIRA Pharmaceuticals’ stock price skyrocketed overnight on the back of surprising good news. The relatively obscure biotech – which trades on the Nasdaq Capital Market under ticker MIRA – closed Wednesday, Oct. 15 at $1.32

16 October 2025

Drug Development · Investment · Medical Innovations · NASDAQ:MIRA · Pharma News · Stock Market

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Volatile Stock Performance in October 2025 Recursion’s stock showed wild swings in early October. On Oct 7, 2025 the shares fell about 5.4% to ~$5.23 amid a broad market slump nasdaq.com. The very next day (Oct 8) the stock rebounded

15 October 2025

Artificial Intelligence · Biotechnology · Investment Trends · NASDAQ:RXRX · Pharma Industry · Stock Market

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

(Source: Nasdaq/GlobeNewswire, Reuters, TipRanks, Finviz, company filings.) Company Overview: Rare Disease Focus and Pipeline Progress Quoin Pharmaceuticals Ltd. is a clinical-stage biotech specializing in rare dermatological diseases. Headquartered in Ashburn, VA, Quoin’s mission is to deliver the first approved therapies

11 October 2025

Financial Analysis · Investing · Market Trends · NASDAQ:QNRX · Pharma News · Stock Market

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Major Corporate & Industry Announcements Clinical Trials & Drug Regulatory Updates Scientific & Medical Research Breakthroughs (Note: The above research highlights were reported in peer-reviewed journals and scientific news outlets around this time, underlining the broader scientific context during the

20 August 2025

Biotechnology · Global News · Health News · Medical Research · NYSE:MDT · Pharmaceuticals

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Sector – Big Deals, Funding, and FDA Drama Pharma & Drug Development – Approvals, Showdowns, and Safety Signals Medical & Clinical Updates – Guidelines and Safety Notices Public Health & Policy – Vaccine Rift, Medicare Cuts, and Wellness Initiatives

19 August 2025

Biotechnology · Healthcare · Industry Updates · Medical News · NASDAQ:ADAP · NASDAQ:ADPT · Pharmaceuticals

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

New Drug Approvals & Clinical Trial Results Mergers, Acquisitions & Partnerships (No other major M&A deals were announced during Aug 17–18, but this Lilly-Superluminal alliance highlights the continued investment in AI-driven R&D.) Regulatory & Policy Updates Public Health & Epidemiology

18 August 2025

Biotech · Health · Medical News · NASDAQ:GBT · NASDAQ:MDGL · NASDAQ:TNXP · NYSE:NVO · NYSE:PFE · Pharma · Research

Breakthrough Cures, Big Pharma Shake-Ups & Health Policy Bombshells – Biotech/Health News (Aug 7–8, 2025)

Scientific Breakthroughs & Discoveries (Aug 7–8, 2025) Regulatory Updates (FDA and Other Agencies) Mergers, Acquisitions & Financial News Public Health & Policy Updates Sources: The information above is sourced from recent press releases, regulatory announcements, and news reports between Aug

8 August 2025

Biotech · Breakthroughs · Health Policy · Medical News · Pharma